Cargando…

High mobility group box 1 (HMGB 1): a new protein in the pathogenesis of ENT inflammatory and infectious diseases

Detalles Bibliográficos
Autores principales:	PASSALI, D., KERN, E., LEI CHEN, R., BELLUSSI, L.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Pacini Editore SpA 2012
Materias:	Letter to the Editor-in-Chief
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3324961/ https://www.ncbi.nlm.nih.gov/pubmed/22500067

Ejemplares similares

High-mobility group box protein 1 expression in inflammatory diseases of the middle ear
por: Bellussi, Luisa Maria, et al.
Publicado: (2017)

The role of High Mobility Group Box 1 chromosomal protein in the pathogenesis of chronic sinusitis and nasal polyposis
por: Bellussi, L.M., et al.
Publicado: (2012)

HMGB1 in the Pathogenesis of Nasal Inflammatory Diseases and its Inhibition as New Therapeutic Approach: A Review from the Literature
por: Bellussi, Luisa Maria, et al.
Publicado: (2017)

The role of high mobility group box 1 (HMGB1) in the pathogenesis of kidney diseases
por: Chen, Qingjie, et al.
Publicado: (2016)

Role of High Mobility Group Box 1 (HMGB1) in SCA17 Pathogenesis
por: Lee, Li-Ching, et al.
Publicado: (2014)

High-mobility group box protein 1 (HMGB1): an alarmin mediating the pathogenesis of rheumatic disease
por: Pisetsky, David S, et al.
Publicado: (2008)

High Mobility Group Box-1 (HMGB1) Participates in the Pathogenesis of Alcoholic Liver Disease (ALD)
por: Ge, Xiaodong, et al.
Publicado: (2014)

The pathogenesis of thromboembolic disease in covid-19 patients: Could be a catastrophic antiphospholipid syndrome?
por: Previtali, Giulia, et al.
Publicado: (2020)

LPS may enhance expression and release of HMGB1 in human nasal epithelial cells in vitro
por: CHEN, D., et al.
Publicado: (2013)

Brief report on the HMGB1-antagonism exerted by glycyrrhizin could be fruitful against COVID-19
por: Ciprandi, Giorgio, et al.
Publicado: (2021)

The role of High Mobility Group Box 1 (HMGB1) in colorectal cancer
por: Süren, Dinç, et al.
Publicado: (2014)

Heparin induced thrombocytopenia in relation to SARS-CoV-2 infection and ABO blood group
por: Ray, Joel G., et al.
Publicado: (2021)

High mobility group box 1 (HMGB1) quantified by ELISA that dose not cross-react with HMGB2
por: Yakabe, K, et al.
Publicado: (2005)

Role of H.E.L.P.-apheresis in the treatment of sudden sensorineural hearing loss in a group of 230 patients
por: BIANCHIN, G., et al.
Publicado: (2011)

Major cardiovascular events after COVID-19, event rates post-vaccination, antiviral or anti-inflammatory therapy, and temporal trends: Correspondence
por: Kleebayoon, Amnuay, et al.
Publicado: (2023)

Developmental expression of high-mobility group box 1 (HMGB1) in the mouse cochlea
por: Liu, Wenjing, et al.
Publicado: (2023)

Double high-dose immunoglobulin for ChAdOx1 nCov-19 vaccine-induced immune thrombotic thrombocytopenia()
por: Huang, Ching-Tai, et al.
Publicado: (2021)

Fatal intracranial hemorrhage in patient with thrombocytopenia and positive HIT antibodies after vaccination with ChAdOx1 nCoV-19 - VITT without thrombosis?
por: Medić, Marijana Grgić, et al.
Publicado: (2022)

High mobility group box 1 (HMGB1) and anti-HMGB1 antibodies and their relation to disease characteristics in systemic lupus erythematosus
por: Abdulahad, Deena A, et al.
Publicado: (2011)

High mobility group box 1 (HMGB1): a pivotal regulator of hematopoietic malignancies
por: Yuan, Shunling, et al.
Publicado: (2020)

High-mobility group box 1 (HMGB1) in COVID-19: extrapolation of dangerous liaisons
por: Al-kuraishy, Hayder M., et al.
Publicado: (2022)

The Role of High Mobility Group Box 1 (HMGB1) in Neurodegeneration: A Systematic Review
por: Ikram, Fathimath Zaha, et al.
Publicado: (2022)

High Mobility Group Box 1 (HMGB1): Potential Target in Sepsis-Associated Encephalopathy
por: DeWulf, Bram, et al.
Publicado: (2023)

The effect of anticoagulation on clinical outcomes in novel Coronavirus (COVID-19) pneumonia in a U.S. cohort
por: Lynn, Lei, et al.
Publicado: (2021)

Preconditioning with high mobility group box 1 protein protects against myocardial ischemia–reperfusion injury
por: Hu, Xiaorong, et al.
Publicado: (2010)

The Role of High Mobility Group Box 1 Protein (HMGB1) in the Immunopathology of Experimental Pulmonary Tuberculosis
por: Hernández-Pando, Rogelio, et al.
Publicado: (2015)

Role of High-Mobility Group Box-1 in Liver Pathogenesis
por: Khambu, Bilon, et al.
Publicado: (2019)

Correction: The Role of High Mobility Group Box 1 Protein (HMGB1) in the Immunopathology of Experimental Pulmonary Tuberculosis
por: Hernández-Pando, Rogelio, et al.
Publicado: (2015)

High mobility group box 1 (HMGB1) acts as an “alarmin” to promote acute myeloid leukaemia progression
por: Yasinska, Inna M., et al.
Publicado: (2018)

High-Mobility Group Box 1 (HMGB1) and Autophagy in Acute Lung Injury (ALI): A Review
por: Qu, Lihua, et al.
Publicado: (2019)

Systemic thromboemboli in patients with Covid-19 may result from paradoxical embolization
por: Rajendram, Rajkumar, et al.
Publicado: (2020)

Rotational thromboelastometry to assess hypercoagulability in COVID-19 patients
por: van Veenendaal, Nadine, et al.
Publicado: (2020)

Asymptomatic deep vein thrombosis in critically ill COVID-19 patients despite therapeutic levels of anti-Xa activity
por: Torres-Machorro, Adriana, et al.
Publicado: (2020)

Anti-Xa monitoring improves low-molecular-weight heparin effectiveness in patients with SARS-CoV-2 infection
por: Trunfio, Mattia, et al.
Publicado: (2020)

More on clinical and computed tomography characteristics of COVID-19 associated acute pulmonary embolism
por: van Dam, L.F., et al.
Publicado: (2020)

Updated hospital associated venous thromboembolism outcomes with 90-days follow-up after hospitalisation for severe COVID-19 in two UK critical care units
por: Doyle, Andrew J., et al.
Publicado: (2020)

Incidence of thrombotic outcomes for patients hospitalized and discharged after COVID-19 infection
por: Bourguignon, Alex, et al.
Publicado: (2020)

COVID-19 associated coagulopathy: Thrombosis, hemorrhage and mortality rates with an escalated-dose thromboprophylaxis strategy
por: Daughety, Molly M., et al.
Publicado: (2020)

Correlation of indirect markers of hypercoagulability with thromboelastography in severe coronavirus 2019
por: Hightower, Stephanie, et al.
Publicado: (2020)

Portal vein thrombosis in a patient with COVID-19
por: Franco-Moreno, A., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_doodm0uamk6qtsfaan7sdb6rjt